Peptides Of 3 To 100 Amino Acid Residues Patents (Class 530/300)
  • Patent number: 9169283
    Abstract: The present invention concerns a method and a kit for the post-synthetic modification of nucleic acids via an inverse Diels-Alder reaction.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: October 27, 2015
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
    Inventors: Manfred Wiessler, Peter Lorenz, Heinz Fleischhacker, Karola Ursula Fleischhacker, Marlen Fleischhacker, Nadja Fleischhacker, Christian Kliem, Andres Jäschke, Juliane Schoch
  • Patent number: 9139614
    Abstract: A modular linker includes an inorganic binding entity having an affinity for a substantially inorganic substance, and an organic binding entity capable of binding with an organic substance covalently bonded thereto. The modular linker is capable of being stored in a stable condition for later use. The modular linker may be synthesized by modifying the inorganic binding entity to be covalently bonded to an organic binding entity and storing the modular linker in an inert environment from about a day up to at least 1 week. The modular linker may be conjugated to an organic substance and to a substantially inorganic substance in substantially a 1:1 ratio. The modular linker may have more than one organic binding entity covalently bonded to an inorganic binding entity or vice-versa. Also, a particular modular linker may have an organic binding entity capable of binding with a nucleic acid sequence.
    Type: Grant
    Filed: April 25, 2007
    Date of Patent: September 22, 2015
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventors: Igor L. Medintz, Lorenzo Berti, Paolo Facci, Hedi M. Mattoussi
  • Patent number: 9133241
    Abstract: The present invention provides, among other things, novel peptides and compositions for treating disease.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: September 15, 2015
    Assignee: TARIX PHARMACEUTICALS LTD.
    Inventor: Richard Franklin
  • Patent number: 9133270
    Abstract: Disclosed herein are recombinant protein scaffolds for use in producing antigen-binding proteins. Related antigen-binding proteins are also provided herein. In addition, nucleic acids encoding such recombinant protein scaffolds and antigen-binding proteins are also described. Vectors and cells useful for expression of the described proteins are also provided, as are methods of use.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: September 15, 2015
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Mark I. Greene, Hongtao Zhang
  • Patent number: 9107875
    Abstract: Disclosed are compositions, kits, and methods for inducing an immune response against disease. The dosage of antigen contained or utilized in the presently disclosed compositions, kits, and methods is substantially lower than dosages conventionally used in the field. The compositions, kits, and methods may be utilized to induce a cell-mediated response, such as a T-helper cell response, and/or a humoral response against a pathogen or a disease. In some embodiments, the compositions, kits, and methods may be utilized to induce preferentially a Th1 response versus other types of immune responses such as a Th2 response.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: August 18, 2015
    Assignee: Auburn University
    Inventors: Yihang Li, Erfan Ullah Chowdhury, Bernhard Kaltenboeck
  • Patent number: 9107948
    Abstract: The application relates to a compound of general formula (I) below: Signal-Linker-Peptide??(I) and to the uses thereof for medical imaging or diagnosis or the preparation of a composition for diagnosis of an MUC5AC pathological condition.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: August 18, 2015
    Assignee: Guerbet
    Inventors: Sébastien Ballet, Walter Gonzalez, Yannick Rossez
  • Patent number: 9090660
    Abstract: Peptide-bound gold metal nanocluster complexes are produced to induce cancer cell death by dramatically inhibiting TrxR activities of the cancer cells. Specificity is shown by selectively designing peptide sequences.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: July 28, 2015
    Inventor: Xueyun Gao
  • Patent number: 9084772
    Abstract: A method of improving the resistance of collagenous tissue to mechanical degradation in accordance with the present invention comprises the step of contacting at least a portion of a collagenous tissue with an effective amount of a crosslinking reagent. The crosslinking reagent includes a crosslinking agent such as genipin and/or proanthrocyanidin. Further, the crosslinking reagent may include a crosslinking agent in a carrier medium. The collagenous tissue to be contacted with the crosslinking reagent is preferably a portion of an intervertebral disc or articular cartilage. The contact between the tissue and the crosslinking reagent is effected by injections directly into the select tissue using a needle. Alternatively, contact between the tissue and the crosslinking reagent is effected by placement of a time-release delivery system such as a gel or ointment, or a treated membrane or patch directly into or onto the target tissue. Contact may also be effected by, for instance, soaking.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: July 21, 2015
    Assignee: Orthopeutics L.P.
    Inventor: Thomas P. Hedman
  • Patent number: 9075059
    Abstract: The present invention provides compositions and methods useful for diagnostic and imaging techniques for detecting and localizing the biomarker Plectin-1. The present invention provides multimeric peptide ligand complexes for targeting Plectin-1, such as the multimeric peptide ligand complex having the formula (?AKTLLPTPGGS(PEG5000))4 KKKKDOTA?A-NH2, to which imaging agents and/or therapeutic agents can be conjugated.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: July 7, 2015
    Assignee: University of Virginia Patent Foundation
    Inventor: Kimberly A. Kelly
  • Patent number: 9068185
    Abstract: Provided are antisense oligonucleotides and other agents that target and modulate nuclear hormone receptors (NHRs) such as the glucocorticoid receptor (GR), compositions that comprise the same, and methods of use thereof.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: June 30, 2015
    Assignee: Sarepta Therapeutics, Inc.
    Inventor: Patrick L. Iversen
  • Patent number: 9064515
    Abstract: Apparatuses, systems, and methods are disclosed related to heat assisted magnetic recording. According to one embodiment, an apparatus that includes a heat sink region and a near field transducer region is disclosed. The near field transducer region is thermally coupled to the heat sink region. At least one of the heat sink region and the near field transducer region includes both an inner core and an outer shell. The inner core can be comprised of a non-plasmonic material and the outer shell can be comprised of a plasmonic material. In further embodiments, the inner core is comprised of a material having a relatively higher electron-phonon coupling constant and the outer shell is comprised of a material having a relatively lower electron-phonon coupling constant.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: June 23, 2015
    Assignee: SEAGATE TECHNOLOGY LLC
    Inventors: Tong Zhao, John C. Duda, Michael Christopher Kautzky
  • Patent number: 9056071
    Abstract: A compound is provided which has a structure I: A-B-C and a method for administering the compound is also provided for use in the prophylaxis and/or treatment of a viral infection, and in particular for preventing and/or inhibiting viral replication, in which A is a quinoline or quinoline-like group, B is a sole amino acid or a peptide or polypeptide having a given amino acid sequence, and C is an O-phenoxy group. According to one embodiment, the compound is a protease inhibitor such as a caspase inhibitor, and the inhibitor can be Q-VD-OPh (N-(2-(quinolyl)valylaspartyl-(2,6-difluorophenoxy)methyl ketone), optionally in an O-methylated form. Antiviral compositions and kits are also provided.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: June 16, 2015
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), INSTITUT PASTEUR, UNIVERSITÉ PARIS-SUD
    Inventors: Jerome Estaquier, Mireille Laforge, Anna Senik
  • Patent number: 9044436
    Abstract: The invention generally relates to compositions and methods of treatment and/or prevention of angiogenesis-related eye diseases using low doses of rhodostomin variants, and in particular, low doses of a fusion protein comprising a rhodostomin variant, wherein the rhodostomin variant is conjugated with a variant of Human Serum Albumin (HSA) where the cysteine residue at position 34 of the HSA amino acid sequence has been replaced with serine.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: June 2, 2015
    Assignees: National Cheng Kung University, National Taiwan University
    Inventors: Woei-Jer Chuang, Wen-Mei Fu, Yen-Lun Huang
  • Publication number: 20150148525
    Abstract: The invention relates to a polypeptide comprising an amino acid having a bicyclo[6.1.0]non-4-yn-9-ylmethanol (BCN) group, particularly when said BCN group is present as: a residue of a lysine amino acid. The invention also relates to a method of producing a polypeptide comprising a BCN group, said method comprising genetically incorporating an amino acid comprising a BCN group into a polypeptide. The invention also relates to an amino acid comprising bicyclo[6.1.0]non-4-yn-9-ylmethanol (BCN), particularly and amino acid which is bicyclo[6.1.0]non-4-yn-9-ylmethanol (BCN) lysine. In addition the invention relates to a PylRS tRNA synthetase comprising the mutations Y271M, L274G and C313A.
    Type: Application
    Filed: May 15, 2013
    Publication date: May 28, 2015
    Inventors: Jason Chin, Kathrin Lang
  • Publication number: 20150148524
    Abstract: A method for the synthesis of an amino acid analogue or a salt, solvate, derivative, isomer or tautomer thereof comprising the steps of: (i) subjecting an amino acid containing a metathesisable group to metathesis with a compound containing a complementary metathesisable group of formula (I) or (II): (Formulae (I), (II)) wherein R1 and R2 are independently selected from H and substituted or unsubstituted C1 to C4 alkyl; each R3 is either absent or independently selected from a heteroatom, a substituted or unsubstituted C1 to C20 alkyl, and a substituted or unsubstituted C1 to C20 alkyl group interrupted by one or more heteroatoms; and each X is independently selected from H and an effector molecule; in the presence of a reagent to catalyse the metathesis to form a dicarba bridge between the amino acid containing a metathesisable group and the compound containing a complementary metathesisable group; and (ii) reducing the dicarba bridge to form a saturated dicarba bridge, wherein the reagent used to catalyse s
    Type: Application
    Filed: July 8, 2013
    Publication date: May 28, 2015
    Inventors: Zhen Wang, Andrea Robinson, Nicolas Daniel Spiccia, William Roy Jackson
  • Patent number: 9039994
    Abstract: This invention relates, e.g., to a method for determining if a subject has myocardial ischemia, comprising (a) providing a blood sample obtained from a subject suspected of having myocardial ischemia; (b) determining in the sample the amount of one or more of the following proteins: (i) Lumican and/or (ii) Extracellular matrix protein 1 and/or (iii) Carboxypeptidase N; and (c) comparing the amount(s) of the protein(s) to a baseline value that is indicative of the amount of the protein in a subject that does not have myocardial ischemia, wherein a statistically significantly increased amount of the protein(s) compared to the baseline value is indicative of myocardial ischemia. Other proteins indicative of myocardial ischemia are also described, as are methods for treating a subject based on a diagnostic procedure of the invention, and kits for carrying out a method of the invention.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: May 26, 2015
    Assignee: The Johns Hopkins University
    Inventors: Jennifer Van Eyk, Simon Sheng, Qin Fu
  • Patent number: 9040664
    Abstract: The invention is directed to a single-step method for rapidly and efficiently preparing protein-polymer conjugates, including an insulin-polymer conjugate. According to the method of the present invention, a protein and hydrophilic polymer are contacted in the presence of at least one organic solvent and at least one metal chelator, under conditions that promote the formation of a conjugate of the protein and polymer. Thus, the invention is directed to the site-specific modification of selected proteins, such as insulin, with poly(ethylene glycol) at residue PheB1. The invention also provides a pharmaceutical formulation for encapsulating the conjugate in a biodegradable polymer.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: May 26, 2015
    Assignee: AntriaBio, Inc.
    Inventors: Kenneth Hinds, Danny Lewis, Paul Schmidt, Kathleen M. Campbell
  • Publication number: 20150141323
    Abstract: The present description provides compositions and methods for producing therapeutic oligomeric compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof.
    Type: Application
    Filed: August 21, 2014
    Publication date: May 21, 2015
    Inventors: Gilles Guichard, Robert Zimmer, Juliette Fremaux
  • Publication number: 20150141321
    Abstract: Provided are 9-base morpholino antisense compounds targeted to polyCUG repeats in the 3?UTR region of dystrophia myotonica protein kinase (DMPK) mRNA, and related methods for treating myotonic dystrophy DM1.
    Type: Application
    Filed: August 20, 2014
    Publication date: May 21, 2015
    Inventors: Ryszard Kole, Gunnar J. Hanson
  • Patent number: 9034585
    Abstract: The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 19, 2015
    Assignee: Health Diagnostic Laboratory, Inc.
    Inventors: Michael S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
  • Patent number: 9034655
    Abstract: Luminescent labels based on aromatic and heterocyclic compounds, including reactive intermediates used to synthesize these compounds, and methods of synthesizing and using these reporter compounds. These labels combine high photostabilities, large Stokes' shifts and contain a pyrimidinium moiety as a water-soluble group. These luminescent compounds relate generally to the following structure: The methods relate generally to the synthesis and/or use of reporter compounds for fluorescence lifetime or fluorescence polarization based applications.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: May 19, 2015
    Assignee: SETA BioMedicals, LLC
    Inventors: Leonid D. Patsenker, Inna G. Yermolenko, Iryna A. Fedyunyaeva, Yelena N. Obukhova, Olga N. Semenova, Ewald A. Terpetschnig
  • Patent number: 9034313
    Abstract: Nucleic acid molecules comprising a nucleotide sequence encoding RANTES and fragments and variants thereof are disclosed. Additionally, nucleic acid molecules and compositions comprising the nucleotide sequence encoding RANTES and fragments and variants thereof in combination with nucleic acid sequences encoding immunogens are provided. Recombinant viral vectors comprising the nucleotide sequence encoding RANTES and fragments and variants thereof with or without a nucleic acid sequence encoding immunogens are also provided as are live attenuated pathogens comprising a nucleotide sequence encoding RANTES and fragments and variants thereof. Methods of modulating immune responses and of inducing an immune response against an immunogen are also disclosed.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: May 19, 2015
    Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
    Inventors: David B Weiner, Jean D Boyer, Michele Kutzler
  • Patent number: 9034586
    Abstract: A pancreatic disease is tested for with high sensitivity even with simple equipment and a simple procedure. Provided is a method of detecting pancreatic disease including detecting a concentration of S100P in at least one of a pancreatic juice and a body fluid containing pancreatic juice collected from a test subject by immunochromatography. Additionally provided is a pancreas testing kit including an immunochromatography device that holds an anti-S100P antibody and a collection vessel that retains a protease inhibitor that inhibits an activity of a protease contained in the pancreatic juice.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: May 19, 2015
    Assignee: OLYMPUS CORPORATION
    Inventors: Hiromi Sanuki, Rie Kataoka, Nao Moriya
  • Publication number: 20150133367
    Abstract: The present invention includes a novel class of highly specific protease inhibitors. In one embodiment, the inhibitors of the invention are ?-helical in structure. In another embodiment, the present invention represents the first demonstration of a highly specific cysteine protease inhibitor.
    Type: Application
    Filed: April 26, 2013
    Publication date: May 14, 2015
    Inventor: Doron C. Greenbaum
  • Publication number: 20150132329
    Abstract: The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient.
    Type: Application
    Filed: May 22, 2012
    Publication date: May 14, 2015
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'ANGERS
    Inventors: Nathalie Labarriere, Francois Lang, Mathilde Bobinet, Anne Rogel
  • Publication number: 20150133305
    Abstract: The present invention is directed to methods, for example phage display assays, for bioengineering peptides that bind to individual distinct nucleotides. Also provided are peptides engineered by such methods. Specifically, cyclic peptides that bind individual distinct nucleotides are provided herein.
    Type: Application
    Filed: November 7, 2008
    Publication date: May 14, 2015
    Inventors: Mineo Yamakawa, Joseph V. Kosmoski, Deane C. Little
  • Publication number: 20150132269
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell.
    Type: Application
    Filed: November 13, 2014
    Publication date: May 14, 2015
    Inventors: Stuart H. Orkin, Andreas Reik, Fyodor Urnov
  • Patent number: 9028844
    Abstract: The present invention relates to a vaccine against Trypanosoma cruzi infection, useful in the prevention and/or treatment of the Chagas disease. More specifically, the present invention relates to a recombinant mutant trans-sialidase enzyme that can be used as an efficient vaccine, without side effects.
    Type: Grant
    Filed: March 14, 2007
    Date of Patent: May 12, 2015
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Roland Contreras, Kristof De Vusser, Silvia Revelli
  • Publication number: 20150126706
    Abstract: 1,3-Dipole-functional compounds (e.g., azide functional compounds) can be reacted with certain alkynes in a cyclization reaction to form heterocyclic compounds. Useful alkynes (e.g., strained, cyclic alkynes) and methods of making such alkynes are also disclosed. The reaction of 1,3-dipole-functional compounds with alkynes can be used for a wide variety of applications including the immobilization of biomolecules on a substrate.
    Type: Application
    Filed: January 7, 2015
    Publication date: May 7, 2015
    Inventors: GEERT-JAN BOONS, JUN GUO, XINGHAI NING, MARGARETHA WOLFERT
  • Patent number: 9023800
    Abstract: Isolated DJ-1 related peptides are disclosed and pharmaceutical compositions comprising same for treating oxidative stress-related disorder.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: May 5, 2015
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Daniel Offen, Nirit Lev, Eldad Melamed
  • Patent number: 9023988
    Abstract: The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production. Macrocycles of the invention include triazole moieties that crosslink amino acid side chains. The cross links can stabilize a secondary structure of a peptidomimetic macrocycle, such as an ?-helix.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: May 5, 2015
    Assignee: Aileron Therapeutics, Inc.
    Inventor: Huw M. Nash
  • Patent number: 9023367
    Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: May 5, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: P. Noel Barrett, Gerald Aichinger, Brian A. Crowe, Ian Livey, Nina Wressnigg
  • Patent number: 9023604
    Abstract: The present invention relates to methods of reversibly staining a target cell. The invention also relates to methods of isolating a target cell or a target cell population that is defined by the presence of at least one common specific receptor molecule. The invention also provides kits that can be used to carry out the methods of the invention.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: May 5, 2015
    Assignee: IBA GmbH
    Inventors: Thomas Schmidt, Christian Stemberger, Dirk H. Busch, Lothar Germeroth
  • Patent number: 9023984
    Abstract: Described is the identification of ZnT8 as an autoantigen target in type I autoimmune diabetes (T1D), other autoimmune disease, and other diabetes-linked diseases and conditions. Also described are a variety of therapeutic, diagnostic, and prognostic tools and methods based on this discovery. The identification of genetic variation in ZnT8 as an important player in the initiation of the disease process and the progression of autoimmunity to clinical diabetes is disclosed.
    Type: Grant
    Filed: December 28, 2007
    Date of Patent: May 5, 2015
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: John C. Hutton, Janet M. Wenzlau, Jan Jensen, Howard Davidson
  • Publication number: 20150118264
    Abstract: The present invention is directed to a pharmaceutical composition including (e.g. for use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components; and as a cargo at least one nucleic acid molecule, and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen. The pharmaceutical composition allows for efficient induction of an adaptive immune response directed against said antigen. The present invention furthermore provides kits, as well as the use of the pharmaceutical composition or the kit as a vaccine, particularly in the treatment of infectious diseases, allergies, autoimmune diseases and tumour or cancer diseases.
    Type: Application
    Filed: January 31, 2013
    Publication date: April 30, 2015
    Applicant: CureVac GMBH
    Inventors: Patrick Baumhof, Thomas Kramps, Söhnke Voss, Karl-Josef Kallen, Mariola Fotin-Mleczek
  • Patent number: 9017690
    Abstract: The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are provided.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: April 28, 2015
    Assignee: BTG International Limited
    Inventors: Robert Anderson, Tim Beissbath, Jason Tye-Din
  • Patent number: 9018348
    Abstract: The present invention relates to modified eIF4G1 peptides, uses thereof and pharmaceutical compositions comprising the modified eIF4G1 peptides.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: April 28, 2015
    Assignee: Agency for Science, Technology and Research
    Inventors: Christopher John Brown, Cheng San Brian Chia
  • Patent number: 9017655
    Abstract: The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: April 28, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stuart Emanuel, Linda Engle, Ray Camphausen, Martin C. Wright, Ginger Chao Rakestraw, Marco Gottardis, Joan Carboni
  • Patent number: 9018168
    Abstract: The present invention relates to a method of treating congestive heart failure (CHF) in a subject comprising administering a peptide derived from atrial natriuretic peptide (ANP) prohormone (eg vessel dilator; VSDL) or a mimetic thereof. In a particular application, the invention provides a method of treating the particular indication known as acute decompensated congestive heart failure (ADCHF). Devices for intravenous or subcutaneous infusion for use in the method of the invention are also disclosed.
    Type: Grant
    Filed: August 11, 2011
    Date of Patent: April 28, 2015
    Assignee: Madeleine Pharmaceuticals Pty Ltd
    Inventor: Thomas Robert Geimer
  • Patent number: 9017955
    Abstract: The present invention is directed to a method of detecting intact fibrinogen, comprising the steps of: a) providing a sample containing at least some fibrinogen optionally converted at least in part to fibrin, and optionally containing thrombin; b) solubilizing the sample in a solubilizing solution that inhibits thrombin activity; c) after optional SDS-PAGE transferring/applying a portion of said sample to a protein-binding membrane; d) reacting the fibrinogen with a primary monoclonal antibody capable of binding to fibrinopeptide A moiety; and e) detecting the quantity of intact fibrinogen in the sample by quantifying the amount of the bound primary monoclonal antibody.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: April 28, 2015
    Assignee: Ethicon, Inc.
    Inventors: Ashley DeAnglis, Elif Burcoglu
  • Patent number: 9018347
    Abstract: Reduced lysine chlorotoxin polypeptides that may be used to generate single species conjugates of chlorotoxin. Conjugates comprising such chlorotoxin polypeptides and pharmaceutical compositions thereof. Methods of using such compositions and/or conjugates.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: April 28, 2015
    Assignee: Morphotek, Inc.
    Inventors: Abdellah Sentissi, Douglas B. Jacoby
  • Publication number: 20150110819
    Abstract: The invention provides Cockroach proteins, peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses and medicaments of such proteins, peptides, subsequences, portions, homologues, variants and derivatives thereof. Such methods, uses and medicaments include modulating an immune response, protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease and inducing immunological tolerance to the allergen (e.g., Cockroach allergen) in a subject.
    Type: Application
    Filed: May 3, 2013
    Publication date: April 23, 2015
    Inventors: Alessandro Sette, Bjoern Peters, Jason Greenbaum
  • Patent number: 9012160
    Abstract: The present invention relates to methods and kits for evaluating the severity of a burn injury, which are based on the detection in a clinical fluid sample of skin metabolism products, such as collagen peptides which are released upon collagen degradation or synthesis.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: April 21, 2015
    Inventor: Abraham Amir
  • Patent number: 9011816
    Abstract: Example systems and methods enhance contrast in MRI images. To facilitate imaging of atherosclerotic plaques, arterial and venous, cardiac, and even tumor tissues and fibrosis, a fibrin-fibronectin complex or disease-related fibronectin specific MRI contrast agent (CLPD) has a specific binding affinity for fibronectin.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: April 21, 2015
    Assignee: Case Western Reserve University
    Inventors: Zheng-Rong Lu, Xueming Wu
  • Patent number: 9012602
    Abstract: Isolated polynucleotides encoding Macaca fascicularis CCL17 (CynoCCL17), polypeptides obtainable from expression of these polynucleotides, recombinant cells, and methods of use are disclosed.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: April 21, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Michael Naso, Mary Ryan, Sandra Santulli-Marotto, Bethany Swencki-Underwood
  • Patent number: 9012603
    Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: April 21, 2015
    Assignee: Biogen Idec Hemophilia Inc.
    Inventors: Adam R. Mezo, Kevin A. McDonnell, Cristina A. Tan Hehir, Alfredo Castro
  • Patent number: 9005902
    Abstract: A method of diagnosing in a host infection by or exposure to a mycobacterium which expresses ESAT-6 comprising (i) contacting a population of T cells from the host with one or more peptides or analogues selected from the peptides represented by SEQ ID NO:1 to 11 and analogues thereof which can bind a T cell receptor which recognises any of the said peptides, and (ii) determining whether the T cells of said T cell population recognise the peptide(s) and/or analogue(s). The method may performed in vivo. Peptides and a kit which enable the method to be carried out are provided.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: April 14, 2015
    Assignee: Oxford Immunotec Limited
    Inventors: Ajit Lalvani, Ansar Pathan
  • Patent number: 9006388
    Abstract: A covalently reactive ligand analogue (CAL) of formula (1): wherein, L1 . . . Lx . . . Lm are components defining a ligand determinant, Lx is a component unit of the ligand determinant selected from the group consisting of an amino acid residue, sugar residue, a fatty acid residue and a nucleotide, L? is a functional group of Lx, Y? is atom, covalent bond or linker, Y? is an optional charged or neutral group Y is a covalently reactive electrophilic group that reacts specifically with a receptor that binds to said ligand determinant, and n is an integer from 1 to 1000 m is an integer from 1 to 30.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: April 14, 2015
    Inventors: Sudhir Paul, Yasuhiro Nishiyama
  • Patent number: 9006389
    Abstract: A repeat protein from a collection of repeat proteins, wherein each repeat protein of said collection comprises a repeat domain, which comprises a set of consecutive repeat modules, wherein the repeat modules have the same fold and stack tightly to create a superhelical structure having a joint hydrophobic core, wherein each of the repeat modules is derived from one or more repeat units and wherein the repeat units comprise framework residues, which contribute to the folding topology of the repeat unit or contribute to an interaction with a neighboring repeat unit, and target interaction residues, which contribute to an interaction with a target substance, wherein the repeat proteins of the collection differ from other repeat proteins in the collection in at least one amino acid position of the repeat modules is described as are related pharmaceuticals and nucleic acid molecules.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: April 14, 2015
    Assignee: Universitat Zurich
    Inventors: Michael Tobias Stumpp, Patrik Forrer, Hans Kaspar Binz, Andreas Pluckthun
  • Patent number: 9006390
    Abstract: The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate MEK activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands, homopolyligands, and heteropolyligands to a cellular localization signal, epitope tag and/or a reporter. The invention also includes polynucleotides encoding the ligands and polyligands.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: April 14, 2015
    Assignee: Intrexon Corporation
    Inventors: David Bachinsky, Jonathan Carson, Amy Atzel, Thomas Reed